7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

MaxCyte to Present Novel Approach to CAR-T for Treatment of Solid Tumors at Biochemical Society in London

October 20, 2015

Gaithersburg, Maryland - – MaxCyte Inc., a world leader in the discovery, development, and manufacture of innovative cell therapies, today announces that it will present its approach to addressing the problem of ‘on-target off-tumor’ toxicity against normal tissue of viral vector-modified CAR T-/NK-cells to the Biochemical Society in London on 20th October 2015.


The presentation, to be made at the Biochemical Society’s focused meeting on Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges, will be given by Madhusudan V. Peshwa, Executive Vice President of Cellular Therapies at MaxCyte.


Dr. Peshwa will detail how MaxCyte deploys a non-viral approach using mRNA CAR transfection to permit prospective control of ‘on-target off-tumor toxicity’ in multiple solid cancers. Collaborating with multiple academic groups, MaxCyte has enabled translation of mRNA CAR therapy into seven human clinical trials to preliminarily confirm safety and anti-tumor activity.


Doug Doerfler, President & CEO of MaxCyte, Inc. said: “We are excited by the potential of our technology and believe that the use of mRNA has multiple advantages over viral vector technology in the delivery of CAR Therapies. In particular, we believe that our approach has the potential to reduce toxicity to normal tissue as well as target solid tumors, a significant unmet medical need. We look forward to discussing our findings with our colleagues at the Biochemical Society and the wider scientific community.”

 

Source



 

Tags:

Please reload

NEWS